oxidopamine has been researched along with alpha-synuclein in 98 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 26 (26.53) | 29.6817 |
| 2010's | 51 (52.04) | 24.3611 |
| 2020's | 21 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Freed, CR; Hurlbert, MS; Prasad, KN; Schaack, J; Zhou, W | 1 |
| Boveris, AD; Cadenas, E; Poderoso, JJ; Riobó, NA; Schöpfer, FJ | 1 |
| Cannizzaro, C; Dass, B; Jenner, P; Owen, A; Rose, S; Tel, BC; Zeng, BY | 1 |
| Alves Da Costa, C; Checler, F; Paitel, E; Vincent, B | 1 |
| Alter, BJ; Jensen, PJ; O'Malley, KL | 1 |
| Checler, F; da Costa, CA; Masliah, E | 1 |
| Caldwell, GA; Caldwell, KA; Cao, S; Gelwix, CC | 1 |
| Chung, KC; Kim, J; Lee, CH; Lee, HJ; Lee, ST; Oh, YJ; Paik, SR; Park, SM; Sung, JY; Um, JW | 1 |
| Diguet, E; Fernagut, PO; Ghorayeb, I; Tison, F | 1 |
| Akaike, A; Hayashi, K; Inden, M; Kitamura, Y; Kondo, J; Nishimura, K; Shimohama, S; Sugimoto, H; Takata, K; Taniguchi, T; Tsuchiya, D; Yanagida, T; Yanagisawa, D | 1 |
| Freed, CR; Zhou, W | 1 |
| Ang, ST; Gung, AY; Leong, SM; Lim, TM; Yap, BP; Zhou, ZD | 1 |
| Eslamboli, A | 1 |
| Lehmensiek, V; Lenk, T; Liebau, S; Schwarz, J; Storch, A; Tan, EM; Zettlmeisl, H | 1 |
| Alves da Costa, C; Brau, F; Cappai, R; Checler, F; Dunys, J; Wilk, S | 1 |
| Bruno, V; Busceti, CL; Falleni, A; Ferrucci, M; Fornai, F; Lazzeri, G; Lenzi, P; Paparelli, A | 1 |
| Chung, KC; Jeong, EI; Kang, KS; Lee, HJ; Oh, Y; Park, J; Sung, JY | 1 |
| Batti, L; Contestabile, A; Crochemore, C; Monti, B; Polazzi, E; Virgili, M | 1 |
| Cao, XB; Qiao, X; Qu, RS; Sun, SG; Wang, JM; Wang, L; Xu, L | 1 |
| Alvarez-Fischer, D; Ferger, B; Hartmann, A; Henze, C; Höglinger, GU; Oertel, WH; Strenzke, C; Westrich, J | 1 |
| Debetto, P; Giusti, P; Guidolin, D; Negro, A; Peroni, D; Recchia, A; Rota, D; Skaper, SD | 1 |
| Caldwell, GA; Caldwell, KA; Fox, SA; Locke, CJ | 1 |
| Borgkvist, A; Brené, S; Fisone, G; Galter, D; Kallunki, P; Lindqvist, E; Lundströmer, K; Olson, L; Pernold, K; Ran, C; Sterky, FH; Westerlund, M | 1 |
| Chang, KA; Cho, D; Cho, SH; Kim, HS; Kim, KY; Kim, S; Lee, SH; Park, CH; Shin, KY; Suh, YH | 1 |
| Chen, B; Xu, SL; Zhou, M | 1 |
| Galvin, JE; Gottschalk, L; Seugnet, L; Shaw, PJ; Suzuki, Y | 1 |
| Hillard, CJ; Kalivendi, SV; Kalyanaraman, B; Yedlapudi, D | 1 |
| Collier, TJ; Dodiya, HB; Kordower, AM; Kordower, JH; Madhavan, L; Paumier, K; Sortwell, C; Steece-Collier, K; Terpstra, B | 1 |
| Alvarez-Fischer, D; Bouillot, C; Castagner, F; Faigle, W; Fuchs, J; Hartmann, A; Joshi, RL; Lombès, A; Massiani-Beaudoin, O; Moya, KL; Oertel, WH; Prochiantz, A; Stettler, O | 1 |
| Caldwell, GA; Caldwell, KA; Harrington, AJ; Tucci, ML | 1 |
| Braun, JE; Faraji, J; Metz, GA; Proft, J; Robbins, JC; Zhao, X; Zucchi, FC | 1 |
| Armentero, MT; Blandini, F | 1 |
| Björklund, A; Decressac, M; Mattsson, B | 1 |
| Calabresi, P; Costa, C; de Iure, A; Di Filippo, M; Di Luca, M; Gardoni, F; Ghiglieri, V; Latagliata, EC; Marti, M; Morari, M; Pascucci, T; Pendolino, V; Picconi, B; Puglisi-Allegra, S; Sgobio, C; Siliquini, S; Spillantini, MG; Tantucci, M; Tozzi, A | 1 |
| An, CN; Pu, XP; Sun, SY | 1 |
| Aebischer, P; Coune, PG; Craveiro, M; Gaugler, MN; Gruetter, R; Mlynárik, V; Schneider, BL | 1 |
| Dunnett, SB; Lelos, MJ; Lindgren, HS | 1 |
| Hwang, BY; Jin, Q; Koppula, S; Noh, SJ; Rajendra Kopalli, S; Shin, KY; Suh, YH | 1 |
| Lira, FS; Lopes-Borges, J; Luciano, T; Pinho, RA; Quevedo, J; Silva, LA; Souza, CT; Trom, CB; Tuon, T; Valvassori, SS | 1 |
| Gong, XL; Li, R; Wang, X; Wang, XM; Wang, Y; Wang, YZ; Yang, ZF | 1 |
| Chang, YZ; Duan, X; Guan, P; Lu, Z; Shi, Z; Wang, Y; Zhao, B; Zhao, Y; Zhao-Wilson, X | 1 |
| Chang, WL; Chen, CS; Fu, RH; Lin, HL; Lin, SZ; Liu, SP; Lu, CH; Shyu, WC; Tsai, RT; Wang, YC; Wang, ZW; Wei, JR | 1 |
| Jaeger, D; Lobb, CJ; Smith, Y; Zaheer, AK | 1 |
| Bubacco, L; Delogu, G; Dettori, MA; Fabbri, D; Hussain, R; Islami, M; Marchiani, A; Migheli, R; Pala, N; Ruzza, P; Sechi, G; Sechi, M; Serra, PA; Siligardi, G; Spissu, Y | 1 |
| Aureli, C; Cassano, T; Chichiarelli, S; Cocciolo, A; d'Erme, M; Fontana, M; Francioso, A; Gaetani, S; Mancini, P; Martire, S; Masci, A; Mosca, L; Romano, A | 1 |
| Bao, XQ; Kong, LB; Kong, XC; Sun, H; Wu, LY; Zhang, D | 1 |
| Chang, WL; Chen, CS; Chen, YM; Fu, RH; Harn, HJ; Huang, JE; Hung, HS; Li, RJ; Lin, SZ; Liu, SP; Shyu, WC; Tsai, SY; Wang, YC | 1 |
| Antonio, T; Dutta, AK; Gogoi, S; Modi, G; Reith, ME; Shah, M; Voshavar, C | 1 |
| Bähr, M; Dohm, CP; Kermer, P; Köhn, A; Liman, J; Lingor, P; Schnieder, M | 1 |
| Dilley, K; Emborg, ME; Joers, V; Jones, C; Rahman, S; Shultz, J; Simmons, H | 1 |
| Bickford, PC; Finneran, DJ; Hudson, C; Moran, P; Morgan, D; Nash, KR; Robinson, J | 1 |
| Albani, D; Batelli, S; Calcagno, E; Forloni, G; Invernizzi, RW; Negro, A; Rodilossi, S | 1 |
| Björklund, A; Decressac, M; Gillberg, L; Mattsson, B; Nobre, A; Papathanou, M; Perlmann, T; Tiklova, K; Volakakis, N | 1 |
| Antonioli, L; Ballabeni, V; Barocelli, E; Bernardini, N; Blandizzi, C; Colucci, R; Fornai, M; Pellegrini, C | 1 |
| Hertz, E; Leinartaité, L; Li, J; Lundius, EG; Svenningsson, P; Yang, J; Zhang, X | 1 |
| Bergstrand, S; Björklund, A; Churchill, MJ; Colino-Sanguino, Y; Decressac, M; Herz, NJ; Ippolito, R; Meshul, CK; Sconce, MD; Tamburrino, A; Wan, OW; Wolf, DA | 1 |
| Calcagno, M; Collins, LM; Dal Bo, G; Gutierrez, H; Monzón-Sandoval, J; Morari, M; O'Keeffe, GW; Sullivan, AM | 1 |
| Hou, L; Ju, C; Li, X; Liu, C; Lv, Y; Wang, X; Wang, Y; Zhang, J; Zhang, Z | 1 |
| Ablat, N; Cao, J; Guo, Y; Han, H; Jiang, H; Lei, H; Li, W; Ma, Y; Pu, X; Qi, X; Ren, R; Shi, C; Sun, Y; Wang, C; Xu, J; Ye, M; Zhao, X | 1 |
| Bhonde, R; Datta, I; Ganapathy, K; Joshi, P; Sowmithra, S | 1 |
| Lin, CY; Tsai, CW | 1 |
| Chen, C; Fang, J; Fu, X; Gu, H; Huang, J; Jiang, M; Jin, L; Li, C; Sun, H; Xu, J | 1 |
| Deng, M; Fang, Y; He, Y; Huang, L; Liu, S; Lu, S | 1 |
| Chalorak, P; Jattujan, P; Meemon, K; Nobsathian, S; Poomtong, T; Sobhon, P | 1 |
| Chen, D; Chen, Z; Fu, Y; Jenner, P; Jin, K; Li, M; Lu, JH; Tang, B; Wang, Q; Wang, R; Wei, X; Yang, X; Zhang, Z; Zou, J | 1 |
| Adlard, PA; Ayton, S; Bal, W; Barnham, KJ; Billings, JL; Bush, AI; Charman, SA; Cherny, RA; Crawford, S; Doble, PA; Finkelstein, DI; Gautier, EC; Gundlach, AL; Hare, DJ; Huggins, P; Kurowska, E; Ma, S; Masters, CL; Parsons, J; Sedjahtera, A; Shackleford, DM; Wilkins, S; Zawisza, IA | 1 |
| Sun, M; Wang, X; Wang, Y; Yang, J; Yang, Z | 1 |
| Abud-Hawa, M; Aluf, Y; Avital, A; Finberg, JPM; Haick, H; Jeries, R; Khatib, S; Loboda, Y; Nakhleh, MK; Vaya, J; Zubedat, S | 1 |
| Aguilar-Morante, D; Alonso-Gil, S; Castaño, JG; Gine, E; Hernandez-Encinas, E; Morales-Garcia, JA; Perez-Castillo, A; Sanchez-Lanzas, R; Santos, A; Sanz-SanCristobal, M; Sierra-Magro, A | 1 |
| Li, K; Li, Y; Na, S; Wu, J; Xie, X; Yang, J; Yang, Z; Yu, X; Yue, J | 1 |
| Cai, Y; Fu, W; Li, J; Li, R; Yang, G; Yang, Z | 1 |
| Jiao, L; Tai, S; Zhai, S; Zhang, C; Zhang, X | 1 |
| Sumathi, T; Varier, KM | 1 |
| Callizot, N; Combes, M; Henriques, A; Poindron, P | 1 |
| Deng, Y; Han, X; Liu, Q; Ma, H; Manzoor, R; Sun, F; Zhang, P | 1 |
| Cao, X; Li, Z; Yan, J; Yang, Z; Zhao, N | 1 |
| Cho, M; Choi, H; Chung, KY; Ham, S; Hwang, S; Kang, H; Kim, D; Kim, H; Kim, S; Ko, HS; Kwon, HS; Lee, GH; Lee, Y; Lee, YS; Shin, HM; Yun, SP | 1 |
| Fu, R; Li, L; Liu, S; Liu, W; Tang, C; Wang, Z; Yin, D | 1 |
| Al Mamun, A; Uddin, MS | 1 |
| Alhakamy, NA; Anwer, MK; Bhattamisra, SK; Choudhury, H; Lim, WM; Md, S; Radhakrishnan, AK; Safian, NH; Shahzad, N; Shak, AT; Xi, LW | 1 |
| Chen, NH; Han, QW; Shi, JG; Wang, S; Yuan, YH; Zhang, CL; Zhou, TT; Zhou, X; Zhu, CG | 1 |
| Björklund, A; Bruzelius, A; Fiorenzano, A; Hoban, DB; Mattsson, B; Mudannayake, J; Nilsson, F; Ottosson, DR; Parmar, M; Shrigley, S | 1 |
| Chen, SY; Gu, Y; Han, R; He, HJ; Li, J; Wang, WW; Xie, C | 1 |
| Gao, H; Jiang, S; Mao, JP; Wang, D; Wang, YL; Yang, XL | 1 |
| Chalorak, P; Limboonreung, T; Meemon, K; Sanguanphun, T | 1 |
| Chen, X; He, CL; He, YN; Law, BY; Long, T; Qin, DL; Tang, Y; Wei, J; Wu, AG; Wu, JM; Wu, Q; Yu, CL; Yu, L; Zhou, XG | 1 |
| Chen, ZH; Dong, ZS; Guan, YQ; Huang, SY; Li, CH; Zeng, ZW; Zhao, WQ | 1 |
| Chang, RCC; Lee, K; Lee, VMY; Luk, KC; Noble, W; Pang, CCC; Sørensen, MH; Trojanowski, JQ | 1 |
| Li, H; Liu, Y; Muhammad, F; Wang, N; Yang, H; Zhao, L; Zhou, Y | 1 |
| Mohajeri, D; Nourazar, MA; Sokouti, H | 1 |
| Duan, Y; Gan, X; Huang, T; Li, S; Ren, J; Si, W; Wang, Z; Wei, J; Wu, K | 1 |
| Jin, S; Jin, T; Li, H; Liu, C; Liu, Y; Long, H; Lu, Y; Peng, Y; Wang, F; Wang, X; Zhao, L | 1 |
| Chen, X; Feng, Y; Gan, J; He, M; He, Z; Li, X; Ma, C; Sun, L; Zhang, X | 1 |
| Chen, WS; Hsieh, DJ; Huang, CY; Ju, DT; Kao, HC; Kuo, CH; Kuo, WW; Liao, SC; Lin, TY; Lin, YJ | 1 |
| Alitalo, O; Cui, H; Elford, JD; Forsberg, MM; Huttunen, KM; Jalkanen, AJ; Kraneveld, A; Myöhänen, TT; Perez-Pardo, P; Tampio, J | 1 |
| Ali, N; Compher, J; Jones, CD; Maffi, SK; McLaughlin, Q; Sane, MS; Tang, H | 1 |
| Chen, HJ; Fu, RH; Hong, SY | 1 |
| Panhelainen, A; Singh, A; Voutilainen, MH | 1 |
5 review(s) available for oxidopamine and alpha-synuclein
| Article | Year |
|---|---|
Marmoset monkey models of Parkinson's disease: which model, when and why?
Topics: alpha-Synuclein; Animals; Callithrix; Disease Models, Animal; Humans; Oxidopamine; Parkinson Disease; Parkinsonian Disorders | 2005 |
Animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Animals, Genetically Modified; Disease Models, Animal; Dopamine Agents; Herbicides; Humans; Neurotoxins; Oxidopamine; Paraquat; Parkinson Disease; Parkinson Disease, Secondary; Sympatholytics | 2012 |
Do α-synuclein vector injections provide a better model of Parkinson's disease than the classic 6-hydroxydopamine model?
Topics: alpha-Synuclein; Animals; Disease Models, Animal; Genetic Vectors; Humans; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats | 2012 |
Gastric motor dysfunctions in Parkinson's disease: Current pre-clinical evidence.
Topics: alpha-Synuclein; Animals; Cholecystokinin; Efferent Pathways; Enteric Nervous System; Gastric Emptying; Gastrointestinal Motility; Gastroparesis; Humans; Mice; Mice, Transgenic; Models, Neurological; Neuromuscular Junction; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Protein Aggregates; Rats; Rotenone; Translational Research, Biomedical; Vagus Nerve | 2015 |
A secret that underlies Parkinson's disease: The damaging cycle.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aldehydes; alpha-Synuclein; Antiparkinson Agents; Biogenic Amines; Drug Design; Gene-Environment Interaction; Humans; Inflammasomes; MicroRNAs; Mitochondria; Models, Neurological; Mutation; Neuroglia; Oxidative Stress; Oxidopamine; Parkinson Disease; Protein Aggregation, Pathological; T-Lymphocyte Subsets | 2019 |
93 other study(ies) available for oxidopamine and alpha-synuclein
| Article | Year |
|---|---|
Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells.
Topics: Adenoviridae; alpha-Synuclein; Animals; Apoptosis; Cell Line, Transformed; Dopamine; Embryo, Mammalian; Gene Transfer Techniques; Humans; Mesencephalon; Mutation; Nerve Tissue Proteins; Neurons; Neurotoxins; Oxidopamine; Parkinson Disease; Rats; Synucleins | 2000 |
The reaction of nitric oxide with 6-hydroxydopamine: implications for Parkinson's disease.
Topics: alpha-Synuclein; Animals; Cattle; Nerve Tissue Proteins; Nitric Oxide; Oxidation-Reduction; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Peroxynitrous Acid; Serum Albumin, Bovine; Superoxide Dismutase; Synucleins; Tyrosine | 2002 |
6-Hydroxydopamine lesioning differentially affects alpha-synuclein mRNA expression in the nucleus accumbens, striatum and substantia nigra of adult rats.
Topics: alpha-Synuclein; Animals; Dopamine; Dopamine Agents; Drug Administration Schedule; Male; Neostriatum; Nerve Tissue Proteins; Neurons; Nucleus Accumbens; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; RNA, Messenger; Substantia Nigra; Sympatholytics; Synucleins; Tyrosine 3-Monooxygenase | 2002 |
Alpha-synuclein lowers p53-dependent apoptotic response of neuronal cells. Abolishment by 6-hydroxydopamine and implication for Parkinson's disease.
Topics: alpha-Synuclein; Apoptosis; Caspase 3; Caspases; Cell Line; Cells, Cultured; Humans; Kidney; Kinetics; Models, Biological; Nerve Tissue Proteins; Neurons; Oxidopamine; Parkinson Disease; Recombinant Proteins; Synucleins; Transfection; Tumor Suppressor Protein p53 | 2002 |
Alpha-synuclein protects naive but not dbcAMP-treated dopaminergic cell types from 1-methyl-4-phenylpyridinium toxicity.
Topics: 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Amino Acid Substitution; Amyloid beta-Peptides; Animals; Bucladesine; Cell Death; Cell Line; Electron Transport; Energy Metabolism; Humans; Hydrogen Peroxide; Ketone Bodies; Mice; Nerve Tissue Proteins; Neurons; Neuroprotective Agents; Neurotoxins; Oxidants; Oxidopamine; Peptide Fragments; Synucleins; Transfection | 2003 |
Beta-synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation: cross-talk with alpha-synuclein and implication for Parkinson's disease.
Topics: alpha-Synuclein; Apoptosis; beta-Synuclein; Caspase 3; Caspases; Enzyme Activation; Humans; Nerve Tissue Proteins; Neurons; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Phenotype; Synucleins; Tumor Suppressor Protein p53 | 2003 |
Torsin-mediated protection from cellular stress in the dopaminergic neurons of Caenorhabditis elegans.
Topics: Adrenergic Agents; alpha-Synuclein; Analysis of Variance; Animals; Animals, Genetically Modified; Blotting, Western; Caenorhabditis elegans; Cationic Amino Acid Transporter 2; Cell Count; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Drug Interactions; Embryo, Mammalian; Embryo, Nonmammalian; Fluorescent Antibody Technique; Gene Expression Regulation; Green Fluorescent Proteins; Humans; Molecular Chaperones; Mutagenesis; Nerve Degeneration; Neurons; Oxidopamine; Time Factors | 2005 |
Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases.
Topics: alpha-Synuclein; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blotting, Western; Catalytic Domain; Cell Line, Tumor; Cell Survival; Coloring Agents; Culture Media; Dopamine; Humans; Immunohistochemistry; Insecta; Kinetics; Male; Matrix Metalloproteinase 3; Matrix Metalloproteinases; Nerve Tissue Proteins; Nitric Oxide; Nitrites; Oxidopamine; Oxygen; Parkinson Disease; Protein Binding; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Substantia Nigra; Synucleins; Tetrazolium Salts; Thiazoles; Time Factors; Transfection | 2005 |
In vivo models of multiple system atrophy.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Corpus Striatum; Levodopa; Macaca fascicularis; Mice; MPTP Poisoning; Multiple System Atrophy; Oxidopamine; Parkinsonian Disorders; Point Mutation; Rats; Substantia Nigra | 2005 |
Serofendic acid prevents 6-hydroxydopamine-induced nigral neurodegeneration and drug-induced rotational asymmetry in hemi-parkinsonian rats.
Topics: Adrenergic Agents; Aldehydes; alpha-Synuclein; Animals; Behavior, Animal; Blotting, Western; CD11b Antigen; Cell Count; Cell Line; Disease Models, Animal; Diterpenes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Functional Laterality; Glial Fibrillary Acidic Protein; Humans; Immunohistochemistry; Male; Neurodegenerative Diseases; Neuroprotective Agents; Oxidopamine; Parkinson Disease, Secondary; Parkinsonian Disorders; Rats; Rats, Wistar; Reactive Oxygen Species; Rotarod Performance Test; Rotation; Substantia Nigra; Synaptophysin; Time Factors; Tyrosine; Tyrosine 3-Monooxygenase | 2005 |
DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity.
Topics: Adenoviridae; alpha-Synuclein; Animals; Apoptosis; Blotting, Western; Carbon; Cell Death; Cell Line; Cell Survival; Cloning, Molecular; Dimerization; DNA, Complementary; Dopamine; Dose-Response Relationship, Drug; Gene Expression Regulation; Glutathione; HSP70 Heat-Shock Proteins; Humans; Hydrogen Peroxide; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Microscopy, Fluorescence; Models, Biological; Mutation; Neurons; Oncogene Proteins; Oxidative Stress; Oxidopamine; Oxygen; Protein Deglycase DJ-1; Rats; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; Up-Regulation | 2005 |
Dopamine-related and caspase-independent apoptosis in dopaminergic neurons induced by overexpression of human wild type or mutant alpha-synuclein.
Topics: 1-Methyl-4-phenylpyridinium; alpha-Methyltyrosine; alpha-Synuclein; Animals; Apoptosis; Caspases; Cell Line; Cell Survival; Dopamine; Gene Expression Regulation; Humans; Mice; Mutation; Neurons; Oxidopamine | 2006 |
Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease.
Topics: Adenosine Triphosphate; alpha-Synuclein; Cell Line; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Energy Metabolism; Humans; Mitochondria; Mutation; Neurons; Neurotoxins; Oxidative Stress; Oxidopamine; Parkinson Disease; Protein Isoforms; Sympatholytics | 2006 |
6-Hydroxydopamine but not 1-methyl-4-phenylpyridinium abolishes alpha-synuclein anti-apoptotic phenotype by inhibiting its proteasomal degradation and by promoting its aggregation.
Topics: 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Animals; Apoptosis; Disease Models, Animal; Herbicides; Humans; Neuroblastoma; Neurons; Oxidopamine; Parkinson Disease; Phenotype; Proteasome Endopeptidase Complex; Tumor Cells, Cultured | 2006 |
Mechanisms involved in the formation of dopamine-induced intracellular bodies within striatal neurons.
Topics: Adrenergic Agents; alpha-Synuclein; Analysis of Variance; Animals; Cells, Cultured; Corpus Striatum; Dopamine; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Inclusion Bodies; Male; Methamphetamine; Mice; Microscopy, Electron, Transmission; Neurons; Oxidopamine; Proteasome Endopeptidase Complex; Rats; Reactive Oxygen Species; Time Factors; Ubiquitin | 2007 |
Alpha-synuclein overexpression reduces gap junctional intercellular communication in dopaminergic neuroblastoma cells.
Topics: Adrenergic Agents; alpha-Synuclein; Cell Communication; Cell Line, Tumor; Cell Survival; Connexins; Dopamine; Gap Junction beta-1 Protein; Gap Junctions; Humans; Hydrogen Peroxide; Immunoprecipitation; Isoquinolines; Mutation; Neuroblastoma; Oxidopamine; Transfection | 2007 |
Alpha-synuclein protects cerebellar granule neurons against 6-hydroxydopamine-induced death.
Topics: alpha-Synuclein; Animals; Apoptosis; Blotting, Western; Cell Death; Cell Nucleus; Cell Survival; Cerebellum; Cytoplasmic Granules; Cytosol; Gene Silencing; Immunoprecipitation; Male; Neurons; Neuroprotective Agents; Oligonucleotides, Antisense; Oxidopamine; Proteasome Endopeptidase Complex; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; Sympatholytics; Translocation, Genetic; Valproic Acid | 2007 |
[Proteolytic stress induced by environmental toxins in dopaminergic neurons: an experimental study].
Topics: 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Animals; Cell Survival; Cytoplasm; Dopamine; Environmental Pollutants; Fluorescent Antibody Technique; Herbicides; Hydrolysis; Insecticides; Neurons; Neurotoxins; Oxidopamine; PC12 Cells; Proteasome Endopeptidase Complex; Rats; Rotenone; Ubiquitin | 2007 |
Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
Topics: Adrenergic Agents; alpha-Synuclein; Animals; Behavior, Animal; Brain Chemistry; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Oxidopamine; Parkinson Disease; Rotarod Performance Test; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 2008 |
Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; alpha-Synuclein; Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Dopamine Agonists; Gene Expression Regulation; Gene Products, tat; Genetic Vectors; Green Fluorescent Proteins; Male; Motor Activity; Oxidopamine; Parkinson Disease; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 2008 |
Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease.
Topics: Acetaminophen; Adrenergic Agents; alpha-Synuclein; Analgesics, Non-Narcotic; Animals; Animals, Genetically Modified; Caenorhabditis elegans; Cell Count; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Gene Expression Regulation; Green Fluorescent Proteins; Neurodegenerative Diseases; Neurons; Oxidopamine; Parkinson Disease; Tyrosine 3-Monooxygenase | 2008 |
Lrrk2 and alpha-synuclein are co-regulated in rodent striatum.
Topics: alpha-Synuclein; Animals; Corpus Striatum; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Female; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Neurons; Oxidopamine; Parkinson Disease; Protein Serine-Threonine Kinases; Rats; Rats, Sprague-Dawley | 2008 |
Alpha-synuclein induces migration of BV-2 microglial cells by up-regulation of CD44 and MT1-MMP.
Topics: alpha-Synuclein; Animals; Brain; Cell Movement; Cell Transplantation; Cells, Cultured; Culture Media, Conditioned; Disease Models, Animal; Hyaluronan Receptors; Matrix Metalloproteinase 14; Mice; Mice, Inbred C57BL; Microglia; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase Kinases; Oxidopamine; Parkinson Disease; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Substantia Nigra; Transfection; Up-Regulation | 2009 |
[Dual effects of different concentrations of alpha-synuclein on the neurotoxicity of 6-hydroxydopamine in SH-SY5Y cells].
Topics: Acetylcysteine; alpha-Synuclein; Apoptosis; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Humans; Neurons; Neuroprotective Agents; Neurotoxins; Oxidopamine; Parkinson Disease | 2009 |
Persistent short-term memory defects following sleep deprivation in a drosophila model of Parkinson disease.
Topics: Age Factors; alpha-Synuclein; Animals; Animals, Genetically Modified; Avoidance Learning; Choice Behavior; Curcumin; Drosophila melanogaster; Drosophila Proteins; Enzyme Inhibitors; Gene Expression Profiling; Humans; Inhibition, Psychological; Light; Maze Learning; Memory, Short-Term; Motivation; Neurotoxins; Oxidopamine; Parkinsonian Disorders; Receptors, Dopamine; Receptors, Dopamine D2; RNA, Messenger; Sleep Deprivation | 2009 |
Oxidants induce alternative splicing of alpha-synuclein: Implications for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; alpha-Synuclein; Alternative Splicing; Animals; Blotting, Western; Cells, Cultured; Disease Models, Animal; Dopamine Agents; Humans; Immunoblotting; Immunoenzyme Techniques; Male; Mesencephalon; Mice; Mice, Inbred C57BL; Neurons; Oxidants; Oxidopamine; Parkinson Disease; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rotenone; Substantia Nigra; Tyrosine 3-Monooxygenase; Uncoupling Agents | 2010 |
Transfer of host-derived α synuclein to grafted dopaminergic neurons in rat.
Topics: alpha-Synuclein; Animals; Dopamine; Fetal Tissue Transplantation; Graft Survival; Humans; Lewy Bodies; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Inbred F344; Sympatholytics | 2011 |
Engrailed protects mouse midbrain dopaminergic neurons against mitochondrial complex I insults.
Topics: alpha-Synuclein; Animals; Cell Count; Cells, Cultured; Chromatography, High Pressure Liquid; Dizocilpine Maleate; Dopamine; Dopamine Plasma Membrane Transport Proteins; Electron Transport Chain Complex Proteins; Embryo, Mammalian; Homeodomain Proteins; In Vitro Techniques; Male; Mesencephalon; Mice; Mice, Inbred C57BL; Mice, Transgenic; NADH Dehydrogenase; Nerve Tissue Proteins; Neurons; Neurotoxins; Nitro Compounds; Oxidopamine; Propionates; RNA, Small Interfering; Rotenone; Stereotyped Behavior; Tyrosine 3-Monooxygenase | 2011 |
Modeling dopamine neuron degeneration in Caenorhabditis elegans.
Topics: alpha-Synuclein; Animals; Caenorhabditis elegans; Disease Models, Animal; Dopaminergic Neurons; Gene Transfer Techniques; Humans; Male; Microinjections; Neurotoxins; Oxidopamine; Parkinson Disease | 2011 |
Identification of bilateral changes in TID1 expression in the 6-OHDA rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Animals; Cell Line, Tumor; Disease Models, Animal; Female; Gene Expression Regulation; Homeostasis; HSP40 Heat-Shock Proteins; Mice; Mitochondria; Molecular Weight; Oxidopamine; Parkinson Disease; Psychomotor Performance; Rats; Rats, Long-Evans; Signal Transduction | 2011 |
Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Female; Medial Forebrain Bundle; Motor Activity; Nerve Degeneration; Neurons; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2012 |
Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease.
Topics: alpha-Synuclein; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Biophysical Phenomena; Disease Models, Animal; Dopamine; Electric Stimulation; Excitatory Postsynaptic Potentials; Exploratory Behavior; Hippocampus; Humans; Levodopa; Long-Term Potentiation; Male; Memory Disorders; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microdialysis; Mutation; Oxidopamine; Parkinson Disease; Patch-Clamp Techniques; Radionuclide Imaging; Rats; Subcellular Fractions; Sympatholytics; Synaptosomes; Tritium; Tyrosine 3-Monooxygenase | 2012 |
DJ-1 protein protects dopaminergic neurons against 6-OHDA/MG-132-induced neurotoxicity in rats.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Apomorphine; Corpus Striatum; Dopamine; Dopaminergic Neurons; Drug Evaluation, Preclinical; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Intracellular Signaling Peptides and Proteins; Ion Channels; Leupeptins; Male; Microinjections; Mitochondrial Membrane Transport Proteins; Mitochondrial Proteins; Mitochondrial Uncoupling Proteins; Motor Activity; Nerve Tissue Proteins; Neuroprotective Agents; Oncogene Proteins; Oxidative Stress; Oxidopamine; Parkinsonian Disorders; Protein Deglycase DJ-1; Rats; Rats, Sprague-Dawley; Substantia Nigra; Superoxide Dismutase; Tyrosine 3-Monooxygenase | 2012 |
An in vivo ultrahigh field 14.1 T (1) H-MRS study on 6-OHDA and α-synuclein-based rat models of Parkinson's disease: GABA as an early disease marker.
Topics: alpha-Synuclein; Animals; Biomarkers; Brain; Early Diagnosis; Female; gamma-Aminobutyric Acid; Magnetic Resonance Spectroscopy; Oxidopamine; Parkinsonian Disorders; Protons; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity | 2013 |
SF-6 attenuates 6-hydroxydopamine-induced neurotoxicity: an in vitro and in vivo investigation in experimental models of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Antioxidants; Avoidance Learning; Behavior, Animal; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Humans; Hydrogen Peroxide; Indigofera; Male; Maze Learning; Memory; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Plant Components, Aerial; Plant Extracts; Reactive Oxygen Species | 2012 |
Physical training exerts neuroprotective effects in the regulation of neurochemical factors in an animal model of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Brain-Derived Neurotrophic Factor; Corpus Striatum; Disease Models, Animal; Male; Motor Activity; Oxidopamine; Parkinson Disease; Physical Conditioning, Animal; Rats; Rats, Wistar; Rotarod Performance Test; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Superoxide Dismutase; Sympatholytics; Thiobarbituric Acid Reactive Substances; Tyrosine 3-Monooxygenase | 2012 |
A DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine, exacerbates neurotoxicity and upregulates Parkinson's disease-related genes in dopaminergic neurons.
Topics: 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Animals; Apoptosis; Azacitidine; Cell Survival; Cells, Cultured; CpG Islands; Decitabine; DNA Methylation; DNA Modification Methylases; Dopaminergic Neurons; Enzyme Inhibitors; Gene Expression Regulation; Humans; Mice; Oxidopamine; Promoter Regions, Genetic; Rats; Rotenone | 2013 |
Neuroprotective effects of aqueous extracts of Uncaria tomentosa: Insights from 6-OHDA induced cell damage and transgenic Caenorhabditis elegans model.
Topics: alpha-Synuclein; Animals; Caenorhabditis elegans; Cat's Claw; Cell Survival; Membrane Potential, Mitochondrial; Neurons; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Plant Extracts; Reactive Oxygen Species | 2013 |
Acetylcorynoline attenuates dopaminergic neuron degeneration and α-synuclein aggregation in animal models of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Antiparkinson Agents; Appetitive Behavior; Berberine Alkaloids; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Dopamine; Dopaminergic Neurons; Green Fluorescent Proteins; Humans; Molecular Structure; Muscle Cells; Nerve Degeneration; Oxidopamine; Parkinsonian Disorders; Repressor Proteins | 2014 |
In vivo electrophysiology of nigral and thalamic neurons in alpha-synuclein-overexpressing mice highlights differences from toxin-based models of parkinsonism.
Topics: Action Potentials; alpha-Synuclein; Animals; Beta Rhythm; Humans; Male; Mice; Motor Cortex; Neurons; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Substantia Nigra; Thalamus | 2013 |
Ceftriaxone blocks the polymerization of α-synuclein and exerts neuroprotective effects in vitro.
Topics: Adrenergic Agents; alpha-Synuclein; Animals; Ceftriaxone; Computer Simulation; Dose-Response Relationship, Drug; Flow Cytometry; Kinetics; Mass Spectrometry; Models, Molecular; Neuroprotective Agents; Oxidopamine; PC12 Cells; Polymerization; Protein Binding; Rats; Time Factors | 2014 |
5-S-cysteinyldopamine neurotoxicity: Influence on the expression of α-synuclein and ERp57 in cellular and animal models of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Biogenic Monoamines; Brain; Cell Line, Tumor; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Glutathione; Glutathione Disulfide; Humans; Male; Mice; Neuroblastoma; Oxidative Stress; Oxidopamine; Parkinson Disease; Protein Carbonylation; Protein Disulfide-Isomerases | 2014 |
Squamosamide derivative FLZ protected dopaminergic neuron by activating Akt signaling pathway in 6-OHDA-induced in vivo and in vitro Parkinson's disease models.
Topics: alpha-Synuclein; Animals; Apomorphine; Benzeneacetamides; Cell Death; Disease Models, Animal; Dopamine Agonists; Dopaminergic Neurons; Male; Motor Activity; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Phenols; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Repressor Proteins; Signal Transduction; Transcription Factors; Tyrosine 3-Monooxygenase | 2014 |
n-butylidenephthalide protects against dopaminergic neuron degeneration and α-synuclein accumulation in Caenorhabditis elegans models of Parkinson's disease.
Topics: alpha-Synuclein; Angelica sinensis; Animals; Antiparkinson Agents; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Drugs, Chinese Herbal; Gene Expression Regulation; Humans; Longevity; Muscle Cells; Oxidopamine; Parkinson Disease; Phthalic Anhydrides; Proteasome Endopeptidase Complex; Repressor Proteins; Transgenes | 2014 |
Multifunctional D2/D3 agonist D-520 with high in vivo efficacy: modulator of toxicity of alpha-synuclein aggregates.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Cell Line, Tumor; Cell Survival; CHO Cells; Cricetulus; Dopamine Agonists; Dopaminergic Neurons; HEK293 Cells; Humans; Male; Mice; Molecular Structure; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Rats, Sprague-Dawley; Receptors, Dopamine D3; Reserpine | 2014 |
BAG1 is neuroprotective in in vivo and in vitro models of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Apoptosis; Cell Line, Tumor; DNA-Binding Proteins; Humans; Mice; Mice, Inbred C57BL; MPTP Poisoning; Neurons; Oxidopamine; Rotenone; Substantia Nigra; Transcription Factors | 2015 |
Cardiac sympathetic denervation in 6-OHDA-treated nonhuman primates.
Topics: Adrenal Medulla; alpha-Synuclein; Animals; Aromatic-L-Amino-Acid Decarboxylases; Autonomic Fibers, Postganglionic; Chromaffin Cells; Disease Models, Animal; Female; Heart; Macaca mulatta; Male; Myocardium; Nerve Degeneration; Oxidopamine; Parkinson Disease, Secondary; Sympathectomy; Tyrosine 3-Monooxygenase | 2014 |
Fractalkine over expression suppresses α-synuclein-mediated neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antigen Presentation; Astrocytes; Chemokine CX3CL1; Dependovirus; Gene Expression Regulation; Genetic Therapy; Genetic Vectors; Glial Fibrillary Acidic Protein; Histocompatibility Antigens Class II; Male; Mice; Microglia; Nerve Tissue Proteins; Neurons; Oxidopamine; Parkinson Disease, Secondary; Parkinsonian Disorders; Promoter Regions, Genetic; Rats; Signal Transduction; Substantia Nigra; Tyrosine 3-Monooxygenase | 2015 |
The Parkinson's disease-related protein DJ-1 protects dopaminergic neurons in vivo and cultured cells from alpha-synuclein and 6-hydroxydopamine toxicity.
Topics: alpha-Synuclein; Animals; Cells, Cultured; Disease Models, Animal; Dopaminergic Neurons; Mesencephalon; Mice; Mice, Inbred C57BL; Mice, Knockout; Mutation; Nerve Degeneration; Oncogene Proteins; Oxidopamine; Parkinson Disease; Peroxiredoxins; Protein Deglycase DJ-1; Up-Regulation | 2015 |
Nurr1 and Retinoid X Receptor Ligands Stimulate Ret Signaling in Dopamine Neurons and Can Alleviate α-Synuclein Disrupted Gene Expression.
Topics: alpha-Synuclein; Animals; Bexarotene; Cells, Cultured; Dopaminergic Neurons; Embryo, Mammalian; Female; Gene Expression Regulation; Homeodomain Proteins; Humans; Mesencephalon; Mice; Mice, Transgenic; Nuclear Receptor Subfamily 4, Group A, Member 2; Oxidopamine; Rats; Rats, Sprague-Dawley; Retinoid X Receptors; Signal Transduction; Stereotyped Behavior; Synapsins; Tetrahydronaphthalenes; Transcription Factors | 2015 |
Overexpression of α-synuclein simultaneously increases glutamate NMDA receptor phosphorylation and reduces glucocerebrosidase activity.
Topics: alpha-Synuclein; Animals; Cell Line, Tumor; Cell Survival; Corpus Striatum; Gene Dosage; Glucosylceramidase; Lysosomes; Mice; Mice, Inbred C57BL; Oxidopamine; Phosphorylation; Protein Subunits; Receptors, N-Methyl-D-Aspartate; Substantia Nigra | 2016 |
Cyclosporin promotes neurorestoration and cell replacement therapy in pre-clinical models of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Cell Transplantation; Cells, Cultured; Cognition Disorders; Cyclosporine; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Enzyme Inhibitors; Female; Humans; Mesencephalon; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Nerve Tissue Proteins; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Time Factors; Tyrosine 3-Monooxygenase | 2015 |
Nociceptin/Orphanin FQ Inhibits the Survival and Axon Growth of Midbrain Dopaminergic Neurons Through a p38-MAPK Dependent Mechanism.
Topics: 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Animals; Axons; Cell Line, Tumor; Cell Survival; Dopaminergic Neurons; Humans; Mesencephalon; Neurotoxins; Nociceptin; Opioid Peptides; Oxidopamine; p38 Mitogen-Activated Protein Kinases; Parkinson Disease; Rats, Sprague-Dawley; RNA, Messenger | 2016 |
Neuroprotection of inositol hexaphosphate and changes of mitochondrion mediated apoptotic pathway and α-synuclein aggregation in 6-OHDA induced parkinson's disease cell model.
Topics: Adrenergic Agents; alpha-Synuclein; Apoptosis; Blotting, Western; Cell Line, Tumor; Flow Cytometry; Humans; Membrane Potential, Mitochondrial; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Phytic Acid | 2016 |
Neuroprotective Effects of A Standardized Flavonoid Extract of Safflower Against Neurotoxin-Induced Cellular and Animal Models of Parkinson's Disease.
Topics: alpha-Synuclein; Animals; Carthamus tinctorius; Cell Survival; Disease Models, Animal; Flavonoids; Kaempferols; Magnetic Resonance Imaging; Male; Microtubules; Molecular Structure; Neurons; Neuroprotective Agents; Neurotoxins; Oxidopamine; Parkinson Disease, Secondary; PC12 Cells; Pigments, Biological; Plant Extracts; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2016 |
Influence of 6-Hydroxydopamine Toxicity on α-Synuclein Phosphorylation, Resting Vesicle Expression, and Vesicular Dopamine Release.
Topics: Adrenergic Agents; alpha-Synuclein; Apoptosis; Blotting, Western; Cell Proliferation; Dopamine; Gene Expression Regulation, Neoplastic; Humans; Membrane Potential, Mitochondrial; Mutation; Neuroblastoma; Oxidative Stress; Oxidopamine; Phosphorylation; Synaptic Vesicles; Tumor Cells, Cultured | 2016 |
Carnosic acid protects SH-SY5Y cells against 6-hydroxydopamine-induced cell death through upregulation of parkin pathway.
Topics: Abietanes; alpha-Synuclein; Animals; Animals, Genetically Modified; Antioxidants; Caenorhabditis elegans; Cell Death; Cell Line, Tumor; Cytoprotection; Humans; Male; Oxidopamine; Rats; Rats, Wistar; Signal Transduction; Ubiquitin-Protein Ligases; Up-Regulation | 2016 |
Mesencephalic astrocyte-derived neurotrophic factor reduces cell apoptosis via upregulating GRP78 in SH-SY5Y cells.
Topics: alpha-Synuclein; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Survival; Dopaminergic Neurons; Endoplasmic Reticulum Chaperone BiP; Heat-Shock Proteins; Humans; Nerve Growth Factors; Neuroprotective Agents; Oxidopamine; Transcriptional Activation; Up-Regulation | 2016 |
β-asarone increases MEF2D and TH levels and reduces α-synuclein level in 6-OHDA-induced rats via regulating the HSP70/MAPK/MEF2D/Beclin-1 pathway: Chaperone-mediated autophagy activation, macroautophagy inhibition and HSP70 up-expression.
Topics: Allylbenzene Derivatives; alpha-Synuclein; Animals; Anisoles; Autophagy; Beclin-1; Female; HSC70 Heat-Shock Proteins; Male; MEF2 Transcription Factors; Mesencephalon; Oxidopamine; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase | 2016 |
Holothuria scabra extracts exhibit anti-Parkinson potential in C. elegans: A model for anti-Parkinson testing.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Biological Products; Caenorhabditis elegans; Disease Models, Animal; Dopaminergic Neurons; Holothuria; Nerve Degeneration; Neuroprotective Agents; Oxidopamine; Parkinson Disease | 2018 |
Cystatin C as a potential therapeutic mediator against Parkinson's disease via VEGF-induced angiogenesis and enhanced neuronal autophagy in neurovascular units.
Topics: alpha-Synuclein; Animals; Autophagy; Caspase 3; Chick Embryo; Chorioallantoic Membrane; Cystatin C; Disease Models, Animal; Gene Expression Regulation; Humans; Injections, Intraventricular; Mice; Mice, Transgenic; Microtubule-Associated Proteins; Neovascularization, Physiologic; Neurons; Neuroprotective Agents; Nuclear Receptor Subfamily 4, Group A, Member 2; Oxidopamine; Parkinson Disease; PC12 Cells; Rats; Signal Transduction; Substantia Nigra; Vascular Endothelial Growth Factor A | 2017 |
The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antiparkinson Agents; Cation Transport Proteins; Cell Line, Tumor; Dogs; Female; Humans; Iron; Male; Mice, Inbred C57BL; Mice, Transgenic; Neurons; Neuroprotective Agents; Oxidative Stress; Oxidopamine; Parkinsonian Disorders; Quinazolinones; Rats; Recombinant Proteins; Substantia Nigra | 2017 |
CpG demethylation in the neurotoxicity of 1-methyl-4-phenylpyridinium might mediate transcriptional up-regulation of α-synuclein in SH-SY5Y cells.
Topics: 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Cell Line, Tumor; Cell Survival; CpG Islands; Demethylation; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; DNA Methyltransferase 3B; Gene Expression Regulation; Humans; Oxidopamine; Promoter Regions, Genetic; Up-Regulation | 2017 |
Altered Volatile Organic Compound Profile in Transgenic Rats Bearing A53T Mutation of Human α-Synuclein: Comparison with Dopaminergic and Serotonergic Denervation.
Topics: 5,7-Dihydroxytryptamine; alpha-Synuclein; Animals; Breath Tests; Corpus Striatum; Discriminant Analysis; Dopaminergic Neurons; Factor Analysis, Statistical; Male; Mutation; Oxidopamine; Parkinsonian Disorders; Rats, Sprague-Dawley; Rats, Transgenic; Serotonergic Neurons; Volatile Organic Compounds | 2018 |
CCAAT/Enhancer binding protein β silencing mitigates glial activation and neurodegeneration in a rat model of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Apoptosis; CCAAT-Enhancer-Binding Protein-beta; Cells, Cultured; Disease Models, Animal; Dopaminergic Neurons; Humans; Male; Mesencephalon; Oxidopamine; Parkinson Disease; Pars Compacta; Rats; Rats, Wistar; RNA Interference; RNA, Small Interfering | 2017 |
The Protective Role of Brain CYP2J in Parkinson's Disease Models.
Topics: alpha-Synuclein; Animals; Apomorphine; Brain; Cell Line, Tumor; Chromatin Immunoprecipitation; Cytochrome P-450 Enzyme System; Disease Models, Animal; Dopaminergic Neurons; Humans; Lipopolysaccharides; Male; Myeloid Differentiation Factor 88; NF-E2-Related Factor 2; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Signal Transduction; Toll-Like Receptor 4 | 2018 |
Glycyrrhizic Acid Alleviates 6-Hydroxydopamine and Corticosterone-Induced Neurotoxicity in SH-SY5Y Cells Through Modulating Autophagy.
Topics: alpha-Synuclein; Apoptosis; Autophagy; Beclin-1; Brain-Derived Neurotrophic Factor; Cell Line, Tumor; Cell Survival; Corticosterone; Cyclic AMP Response Element-Binding Protein; Glycyrrhizic Acid; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Microtubule-Associated Proteins; Neuroprotective Agents; Oxidopamine; Parkinson Disease, Secondary; Signal Transduction | 2018 |
[Alpha-lipoic acid inhibits the expression of α-synuclein in PC12 cells induced by 6-hydroxydopamine and its mechanism].
Topics: alpha-Synuclein; Animals; Oxidopamine; PC12 Cells; Rats; Thioctic Acid | 2018 |
Hinokitiol Offers Neuroprotection Against 6-OHDA-Induced Toxicity in SH-SY5Y Neuroblastoma Cells by Downregulating mRNA Expression of MAO/α-Synuclein/LRRK2/PARK7/PINK1/PTEN Genes.
Topics: alpha-Synuclein; Apoptosis; Cell Line, Tumor; Down-Regulation; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Monoamine Oxidase; Monoterpenes; Neuroprotective Agents; Oxidative Stress; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Protein Deglycase DJ-1; Protein Kinases; PTEN Phosphohydrolase; RNA, Messenger; Tropolone | 2019 |
Necrosis, apoptosis, necroptosis, three modes of action of dopaminergic neuron neurotoxins.
Topics: 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Animals; Apoptosis; Cells, Cultured; Dopaminergic Neurons; Embryo, Mammalian; Energy Metabolism; Female; Humans; Mesencephalon; Mitochondria; Necroptosis; Necrosis; Neurotoxins; Oxidative Stress; Oxidopamine; Parkinson Disease; Primary Cell Culture; Protein Aggregation, Pathological; Rats; Rotenone | 2019 |
Gastrodin protects dopaminergic neurons via insulin-like pathway in a Parkinson's disease model.
Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Benzyl Alcohols; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Chemotaxis; Dopaminergic Neurons; Dose-Response Relationship, Drug; Forkhead Transcription Factors; Glucosides; Neuroprotection; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Receptor, Insulin; Signal Transduction | 2019 |
Cell-Based Screen Using Amyloid Mimic β23 Expression Identifies Peucedanocoumarin III as a Novel Inhibitor of α-Synuclein and Huntingtin Aggregates.
Topics: alpha-Synuclein; Amyloid; Coumarins; HEK293 Cells; High-Throughput Screening Assays; Humans; Huntingtin Protein; Neuroblastoma; Nuclear Proteins; Oxidopamine; Peptides; Protein Aggregates; Tetracycline | 2019 |
Regular Aerobic Exercise-Alleviated Dysregulation of CAMKIIα Carbonylation to Mitigate Parkinsonism via Homeostasis of Apoptosis With Autophagy.
Topics: Aging; alpha-Synuclein; Animals; Apoptosis; Autophagy; Beclin-1; Behavior, Animal; Calcium-Binding Proteins; Corpus Striatum; Exercise Therapy; Homeostasis; Microtubule-Associated Proteins; Oxidopamine; Parkinson Disease, Secondary; Physical Conditioning, Animal; Protein Carbonylation; Rats | 2020 |
KDS2010: A Potent Highly Selective and Reversible MAO-B Inhibitor for Alzheimer's Disease.
Topics: alpha-Synuclein; Alzheimer Disease; Animals; Biological Transport; Blood-Brain Barrier; Drug Design; Female; Haplorhini; Humans; Male; Mice; Models, Animal; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Oxidopamine; Structure-Activity Relationship | 2020 |
Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson's disease.
Topics: Administration, Intranasal; alpha-Synuclein; Animals; Blood-Brain Barrier; Cell Line, Tumor; Chitosan; Disease Models, Animal; Dopamine Agonists; Drug Carriers; Female; Haloperidol; Humans; Male; Nanoparticles; Neurons; Oxidopamine; Parkinson Disease, Secondary; Particle Size; Rats; Tetrahydronaphthalenes; Thiophenes; Toxicity Tests, Acute | 2020 |
A bibenzyl compound 20C protects rats against 6-OHDA-induced damage by regulating adaptive immunity associated molecules.
Topics: alpha-Synuclein; Animals; Antioxidants; Bibenzyls; Brain; Cytokines; Disease Models, Animal; Dopaminergic Neurons; Endocytosis; Enzyme Inhibitors; Inflammation Mediators; Male; Microglia; Neuroprotective Agents; Nitric Oxide Synthase Type II; Oxidative Stress; Oxidopamine; Parkinsonian Disorders; PC12 Cells; Rats; Rats, Sprague-Dawley; Signal Transduction | 2021 |
Grafts Derived from an α-Synuclein Triplication Patient Mediate Functional Recovery but Develop Disease-Associated Pathology in the 6-OHDA Model of Parkinson's Disease.
Topics: alpha-Synuclein; Animals; Dopaminergic Neurons; Humans; Induced Pluripotent Stem Cells; Oxidopamine; Parkinson Disease; Rats; Synucleinopathies | 2021 |
Administration of quercetin improves mitochondria quality control and protects the neurons in 6-OHDA-lesioned Parkinson's disease models.
Topics: alpha-Synuclein; Animals; Cell Line, Tumor; Disease Models, Animal; Gene Knockdown Techniques; HeLa Cells; Humans; Male; Mitochondria; Mitophagy; Neurons; Neuroprotective Agents; Oxidative Stress; Oxidopamine; Parkinson Disease, Secondary; Protein Kinases; Quercetin; Rats; Ubiquitin-Protein Ligases | 2021 |
Pramipexole attenuates 6-OHDA-induced Parkinson's disease by mediating the Nurr1/NF-κB pathway.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Disease Models, Animal; NF-kappa B; Nuclear Receptor Subfamily 4, Group A, Member 2; Oxidopamine; Parkinson Disease; Pramipexole; Rats; Signal Transduction | 2021 |
Neurorescue Effects of Frondoside A and Ginsenoside Rg3 in
Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Apoptosis; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Disease Models, Animal; Dopaminergic Neurons; Gene Expression Regulation; Ginsenosides; Glycosides; Longevity; Nerve Degeneration; Oxidopamine; Parkinson Disease; Proteolysis; Triterpenes | 2021 |
Ferulic Acid Exerts Neuroprotective Effects via Autophagy Induction in
Topics: alpha-Synuclein; Animals; Apoptosis; Autophagy; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Coumaric Acids; Dopaminergic Neurons; Gene Knockdown Techniques; Hydrogen Peroxide; Locomotion; Neuroprotective Agents; Oxidopamine; Parkinson Disease; PC12 Cells; Rats; Reactive Oxygen Species; RNA Interference; Signal Transduction | 2022 |
Nano-MgO composites containing plasmid DNA to silence SNCA gene displays neuroprotective effects in Parkinson's rats induced by 6-hydroxydopamine.
Topics: alpha-Synuclein; Animals; DNA; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Plasmids; Rats | 2022 |
Investigating key factors underlying neurodegeneration linked to alpha-synuclein spread.
Topics: alpha-Synuclein; Animals; Mice; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2022 |
Neuroprotective effects of cannabidiol on dopaminergic neurodegeneration and α-synuclein accumulation in C. elegans models of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Antioxidants; Caenorhabditis elegans; Cannabidiol; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Neuroprotective Agents; Oxidopamine; Parkinson Disease | 2022 |
6-Hydroxydopamine-Induced Neurotoxicity in Rat Model of Parkinson's Disease: Is Reversed via Anti-Oxidative Activities of Curcumin and Aerobic Exercise Therapy.
Topics: alpha-Synuclein; Animals; Antioxidants; Apomorphine; Curcumin; Disease Models, Animal; Glutathione Peroxidase; Malondialdehyde; Neuroprotective Agents; Neurotoxicity Syndromes; Neurotoxins; Oxidopamine; Parkinson Disease; Rats; Substantia Nigra | 2022 |
Pathological α-synuclein accumulation, CSF metabolites changes and brain microstructures in cynomolgus monkeys treated with 6-hydroxydopamine.
Topics: alpha-Synuclein; Animals; Brain; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Macaca fascicularis; Nerve Degeneration; Oxidopamine; Parkinson Disease; Substantia Nigra | 2023 |
Cannabidivarin alleviates α-synuclein aggregation via DAF-16 in Caenorhabditis elegans.
Topics: alpha-Synuclein; Animals; Autism Spectrum Disorder; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Cannabinoids; Forkhead Transcription Factors; Oxidopamine; Parkinson Disease | 2023 |
Potential Therapeutic Effects of Policosanol from Insect Wax on Caenorhabditis elegans Models of Parkinson's Disease.
Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Caenorhabditis elegans; Disease Models, Animal; Dopaminergic Neurons; Fatty Alcohols; Neurodegenerative Diseases; Oxidopamine; Parkinson Disease; Reactive Oxygen Species | 2023 |
Ginkgolide A improves the pleiotropic function and reinforces the neuroprotective effects by mesenchymal stem cell-derived exosomes in 6-OHDA-induced cell model of Parkinson's disease.
Topics: alpha-Synuclein; Dopamine; Exosomes; Humans; Mesenchymal Stem Cells; Neuroprotective Agents; Oxidopamine; Parkinson Disease | 2023 |
Nigrostriatal 6-hydroxydopamine lesions increase alpha-synuclein levels and permeability in rat colon.
Topics: alpha-Synuclein; Animals; Brain; Colon; Dopamine; Oxidopamine; Parkinson Disease; Rats | 2023 |
6-hydroxydopamine affects multiple pathways to induce cytotoxicity in differentiated LUHMES dopaminergic neurons.
Topics: alpha-Synuclein; Apoptosis; Dopaminergic Neurons; Humans; Oxidopamine; Parkinson Disease | 2023 |
Syringin Prevents 6-Hydroxydopamine Neurotoxicity by Mediating the MiR-34a/SIRT1/Beclin-1 Pathway and Activating Autophagy in SH-SY5Y Cells and the
Topics: alpha-Synuclein; Animals; Autophagy; Beclin-1; Caenorhabditis elegans; Humans; MicroRNAs; Neuroblastoma; Neurotoxicity Syndromes; Oxidopamine; Parkinson Disease; Sirtuin 1 | 2023 |
Feasibility of combining alpha-synuclein aggregation and 6-OHDA in embryonic midbrain culture for modeling dopamine neuron degeneration.
Topics: alpha-Synuclein; Animals; Dopamine; Feasibility Studies; Mesencephalon; Mice; Nerve Degeneration; Oxidopamine; Parkinson Disease; Synucleinopathies | 2023 |